Cleared By India's Drug Controller, GVK Bio Expects To Complete Phase III Trials On Wyeth’s Prevnar 13 By Year End
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - GVK Biosciences, the clinical research organization undertaking Phase III clinical trials for Wyeth's advanced version of Prevnar vaccine said it hopes to complete the studies in 12 to 13 centers by the end of the year. Wyeth is testing the vaccine in India along with many other countries to examine the new product that will fight 13 strains of bacterial infections instead of the present seven